Myeloma Minute: Looking Ahead to the Future of Myeloma


| INNOVATION | 30th Anniversary


On the Eve of 2020, Celebrating Three Decades of Progress and a Bright Future Ahead

In 2020, the IMF will celebrate the organization’s 30th Anniversary. While looking back on our accomplishments in his year-end blog, IMF Chairman Dr. Brian G.M. Durie predicts an even brighter future ahead. Exciting new treatments offer hope of improved outcomes. And accelerated research is bringing us closer to prevention and a cure.


| EDUCATION | Survey


We Want to Hear from You!

The IMF is conducting a survey to better understand how patients with multiple myeloma and smoldering myeloma are treated. We ask you to consider doing two things to help us:

  • If you are a patient, we hope that you will participate in this survey.
  • Please forward this e-mail and survey to other IMF community members so additional patients are able to participate.

We greatly appreciate and value your time and input to this survey. It should only take 5-10 minutes to complete. This information will continue to help us serve the needs of the myeloma community worldwide. Thank you!


| INSPIRATION | The Holidays


| INNOVATION | Save the Date


In the Spirit of the Season, the IMF Takes Time with Our Loved Ones
Tune in to the Best of ASH 2019 Webinar

The IMF Board of Directors generously allows our staff the time to spend with our own families at year end. Our office will be closed from Monday, December 23, 2019, to Monday, January, 6, 2020. Yet, it’s not too late to make your year-end contribution online. Gifts received online before midnight PT on December 31, 2019, will be eligible for a 2019 deduction. Thank you, and have a safe and wonderful holiday!

Dr. Brian G.M. Durie discusses key takeaways from the 2019 American Society of Hematology (ASH) annual conference for patients, caregivers, and others. Save the date: Thursday January 9, 2020, at 4:00 p.m. PT / 7:00 p.m. ET for this webinar featuring an ASH summary.


Register Now Button.png

| INNOVATION | Latest Research


DREAMM-2 Study Demonstrates Important Results with Belantamab Mafodotin (GSK2857916) for Patients with Relapsed/Refractory Mulitple Myeloma

The Lancet Oncology published results from the pivotal DREAMM-2 study. This study uses belantamab mafodotin, a humanized, anti-BCMA (immuno-conjugate against B-cell maturation antigen). It demonstrated a clinically meaningful 31% overall response rate (ORR) in heavily pre-treated multiple myeloma patients. GSK, the manufacturer of this drug, has submitted Biologics License Application to the Food and Drug Administration for belantamab mafodotin. If approved, the drug would be the first anti-BCMA therapy available in the U.S.


| EDUCATION | Seminar


Register Now for the 2020 IMF Patient & Family Seminar in Boca Raton, FL

From March 1314, 2020, the IMF will host a Patient & Family Seminar at the Boca Raton Marriott (5150 Town Center Circle) in Boca Raton, FL. Choose between two registration packages—either attend Friday’s half-day session and the all-day session Saturday, or attend the Saturday session only. Connect with other patients and caregivers. Together, we can learn, build community, and share our stories.

Register Now Button.png

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

Clinical Trial Fact Sheets

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Amy’s Opal Jewelry Fundraiser

January 9, 2020
Best of ASH 2019

January 10, 2020
Magical Miles for Myeloma
Walt Disney World - Orlando

March 13-14, 2020
IMF Patient & Family Seminar
Boca Raton, FL

May 8-9, 2020
IMF Patient & Family Seminar
Seattle, WA

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Bristol-Myers Squibb, Genentech, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.